CL2017001275A1 - Análogos ligados de urea sustituidos como moduladores de sirtuina - Google Patents

Análogos ligados de urea sustituidos como moduladores de sirtuina

Info

Publication number
CL2017001275A1
CL2017001275A1 CL2017001275A CL2017001275A CL2017001275A1 CL 2017001275 A1 CL2017001275 A1 CL 2017001275A1 CL 2017001275 A CL2017001275 A CL 2017001275A CL 2017001275 A CL2017001275 A CL 2017001275A CL 2017001275 A1 CL2017001275 A1 CL 2017001275A1
Authority
CL
Chile
Prior art keywords
disorders
diseases
sirtuin modulators
analogs substituted
modulators
Prior art date
Application number
CL2017001275A
Other languages
English (en)
Inventor
James Lamond Ellis
Karen Anderson Evans
Ryan Michael Fox
William Henry Miller
Mark Andrew Seefeld
Original Assignee
Glaxosmithkline Intellectual Property N 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property N 2 Ltd filed Critical Glaxosmithkline Intellectual Property N 2 Ltd
Publication of CL2017001275A1 publication Critical patent/CL2017001275A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A NUEVOS COMPUESTOS ANÁLOGOS DE UREA UNIDOS SUSTITUIDOS DE FORMULA (I) O SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, COMPOSICIONES FARMACÉUTICAS CORRESPONDIENTES, PROCESOS PARA PREPARAR Y USAR DICHOS COMPUESTOS, SOLOS O EN COMBINACIÓN CON OTROS AGENTES TERAPÉUTICOS, COMO MODULADORES DE SIRTUINA ÚTILES, PARA AUMENTAR LA LONGEVIDAD DE UNA CÉLULA, Y EN EL TRATAMIENTO Y/O LA PREVENCIÓN DE UNA AMPLIA DIVERSIDAD DE ENFERMEDADES Y TRASTORNOS, QUE INCLUYEN, PERO SIN LIMITACIÓN, POR EJEMPLO, ENFERMEDADES NEURODEGENERATIVAS, ENFERMEDAD CARDIOVASCULAR, TRASTORNOS DE LA COAGULACIÓN SANGUÍNEA, INFLAMACIÓN, CÁNCER Y/O ENROJECIMIENTO ASÍ COMO ENFERMEDADES O TRASTORNOS QUE SE BENEFICIARÍAN DE LA ACTIVIDAD MITOCONDRIAL AUMENTADA.</p>
CL2017001275A 2014-11-19 2017-05-18 Análogos ligados de urea sustituidos como moduladores de sirtuina CL2017001275A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462081916P 2014-11-19 2014-11-19

Publications (1)

Publication Number Publication Date
CL2017001275A1 true CL2017001275A1 (es) 2017-12-15

Family

ID=54705247

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001275A CL2017001275A1 (es) 2014-11-19 2017-05-18 Análogos ligados de urea sustituidos como moduladores de sirtuina

Country Status (21)

Country Link
US (4) US20180319810A1 (es)
EP (4) EP3221316A1 (es)
JP (4) JP2017534664A (es)
KR (4) KR20170083135A (es)
CN (4) CN107108627A (es)
AU (4) AU2015348941A1 (es)
BR (4) BR112017010595A2 (es)
CA (4) CA2968030A1 (es)
CL (1) CL2017001275A1 (es)
CO (1) CO2017004994A2 (es)
CR (1) CR20170209A (es)
DO (1) DOP2017000123A (es)
EA (1) EA201791074A1 (es)
ES (1) ES2823748T3 (es)
IL (1) IL252252A0 (es)
MX (1) MX2017006658A (es)
PE (1) PE20171257A1 (es)
PH (1) PH12017500913A1 (es)
RU (3) RU2017120858A (es)
SG (1) SG11201703824QA (es)
WO (4) WO2016079709A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086088A2 (en) 2014-11-25 2016-06-02 Northwestern University Wound healing through sirt1 overexpression
CN108329388A (zh) * 2018-01-18 2018-07-27 天津市湖滨盘古基因科学发展有限公司 一种人的沉默配型信息调节蛋白突变蛋白及其应用
CN108707150B (zh) * 2018-05-14 2021-04-16 江苏惠利生物科技有限公司 一种咪唑并吡嗪医药中间体的制备方法
CN108395436B (zh) * 2018-05-14 2021-01-12 鹤壁市人民医院 一种咪唑并吡嗪医药中间体的制备方法
CN110478339A (zh) * 2019-08-12 2019-11-22 昆明理工大学 紫铆因在制备靶向恢复突变p53构象药物中的应用
CN114341117A (zh) * 2019-09-02 2022-04-12 默克专利有限公司 用于有机电致发光器件的材料
CN114890955A (zh) * 2022-06-23 2022-08-12 江西瑞威尔生物科技有限公司 一种n取代吗啉类有机化合物的制备工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO2006094210A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Tetrahydroquinoxalinone sirtuin modulators
UA108596C2 (xx) 2007-11-09 2015-05-25 Інгібітори пептиддеформілази
AU2010319842A1 (en) * 2009-10-29 2012-05-17 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators
JP2015504868A (ja) * 2011-12-12 2015-02-16 エスエムビー・イノベーション・アンパルトセルスカブＳＭＢ Ｉｎｎｏｖａｔｉｏｎ ＡｐＳ サーチュイン結合および調節に有用な新規複素環化合物
AU2014265671B2 (en) 2013-05-13 2017-04-06 Glaxosmithkline Llc Substituted bridged urea analogs as sirtuin modulators

Also Published As

Publication number Publication date
EP3221317A1 (en) 2017-09-27
CN107207509A (zh) 2017-09-26
JP6806679B2 (ja) 2021-01-06
CR20170209A (es) 2017-07-17
KR20170083133A (ko) 2017-07-17
US20170355705A1 (en) 2017-12-14
JP2017534663A (ja) 2017-11-24
AU2015348944A1 (en) 2017-06-01
KR20170083134A (ko) 2017-07-17
CO2017004994A2 (es) 2017-09-20
JP2017534662A (ja) 2017-11-24
EP3221316A1 (en) 2017-09-27
CN107207521A (zh) 2017-09-26
RU2017120858A (ru) 2018-12-19
CN107207520A (zh) 2017-09-26
US20170362234A1 (en) 2017-12-21
RU2017120857A (ru) 2018-12-19
IL252252A0 (en) 2017-07-31
CA2968027A1 (en) 2016-05-26
CA2968030A1 (en) 2016-05-26
PH12017500913A1 (en) 2017-12-04
PE20171257A1 (es) 2017-08-28
AU2015348942A1 (en) 2017-06-01
SG11201703824QA (en) 2017-06-29
EP3221317B1 (en) 2020-07-22
CN107108627A (zh) 2017-08-29
EP3220918A1 (en) 2017-09-27
MX2017006658A (es) 2018-01-15
BR112017010601A2 (pt) 2017-12-26
JP2017534664A (ja) 2017-11-24
BR112017010602A2 (pt) 2017-12-26
BR112017010595A2 (pt) 2018-01-02
US20180319810A1 (en) 2018-11-08
CN107207509B (zh) 2020-04-21
EA201791074A1 (ru) 2017-10-31
CA2968032A1 (en) 2016-05-26
EP3221322A1 (en) 2017-09-27
WO2016079709A1 (en) 2016-05-26
US10072011B2 (en) 2018-09-11
AU2015348943A1 (en) 2017-06-01
WO2016079710A1 (en) 2016-05-26
DOP2017000123A (es) 2017-08-15
AU2015348942B2 (en) 2018-07-05
WO2016079712A1 (en) 2016-05-26
ES2823748T3 (es) 2021-05-10
AU2015348941A1 (en) 2017-06-01
JP2017534665A (ja) 2017-11-24
WO2016079711A1 (en) 2016-05-26
BR112017010599A2 (pt) 2017-12-26
KR20170087907A (ko) 2017-07-31
RU2017120855A (ru) 2018-12-19
CA2968029A1 (en) 2016-05-26
US20190048016A1 (en) 2019-02-14
KR20170083135A (ko) 2017-07-17

Similar Documents

Publication Publication Date Title
CL2017001275A1 (es) Análogos ligados de urea sustituidos como moduladores de sirtuina
DOP2016000094A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
PE20150887A1 (es) Compuestos de benceno sustituidos
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
EA201890573A1 (ru) Новые замещенные 6-6-бициклическим ароматическим кольцом аналоги нуклеозидов для применения в качестве ингибиторов prmt5
ECSP11011517A (es) Compuestos antivirales
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
DOP2017000013A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
DOP2016000194A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
NI201700056A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer
PE20151067A1 (es) Inhibidores de autotaxina
ECSP13012417A (es) Derivados de ácido napht-2-ilacético para tratar sida
UY33735A (es) Compuestos antivirales
CU24487B1 (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores de gamma ror
GT201400102A (es) 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
ECSP13013068A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
EA201790781A2 (ru) Противовирусные соединения
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
UY35146A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
PE20151438A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos